Joe Cabral joined Flagship Pioneering as an Associate in 2019 after completing the firm’s summer Fellows program the previous year. At Flagship, Joe works as part of a venture-creation team to explore opportunities for innovation and develop first-in-category life science companies. In this capacity, he develops the science, intellectual property, and corporate strategy that form the foundation of breakthrough startups.
Prior to joining Flagship, Joe earned his M.B.A. from the University of Michigan’s Ross School of Business, with emphases in healthcare and entrepreneurship. Before Ross, Joe was an early employee at Moderna, a Flagship company pioneering messenger RNA therapeutics. At Moderna, Joe helped build molecular biology and informatics capabilities, and subsequently applied next gen sequencing and software engineering techniques to better understand the biophysical properties of modified nucleotides and full-length mRNA therapies in order to engineer more potent medicines. In addition to his role evaluating mRNA secondary structure and translation with the computational sciences team, Joe played a key role in the early development of the personalized cancer vaccine program, which is now in clinical trials.
While at Michigan, Joe was elected as Managing Director of the Zell Lurie Commercialization Fund, a cross-disciplinary, student-run venture capital fund that invests in early-stage technologies stemming from the UofM community. In addition, Joe received multiple awards recognizing his outstanding performance in entrepreneurship and venture capital during his time at Ross.
In addition to his M.B.A. from the University of Michigan, Joe received his B.S. in Biological Sciences and M.S. in Genomics from the University of Connecticut. During his undergraduate and master’s work, Joe researched alternative gene regulation induced by small RNAs encoded by Epstein Barr Virus.